Management of inherited von Willebrand disease in 2007

Annals of Medicine

Volumn 39, Issue 5, 2007, Pages 346-358

  Federici, Augusto B ^a   Mannucci, Pier Mannuccio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bleedings; Desmopressin; Genotype; Molecular and prenatal diagnosis; Phenotype; Secondary long term prophylaxis; Surgery; Von Willebrand disease; Von Willebrand factor; Von Willebrand factor concentrates

Indexed keywords

AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; ESTROGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RISTOCETIN; THROMBOCYTE RECEPTOR; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

ADJUVANT THERAPY; BLOOD TRANSFUSION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MECHANISM; FLUSHING; GENE MUTATION; HEADACHE; HEART INFARCTION; HEART VOLUME; HEMOPHILIA A; HUMAN; HYPONATREMIA; LABORATORY DIAGNOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SEIZURE; SIDE EFFECT; STROKE; SURGICAL TECHNIQUE; TACHYCARDIA; THROMBOSIS; VON WILLEBRAND DISEASE;

BLOOD COMPONENT TRANSFUSION; DEAMINO ARGININE VASOPRESSIN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMORRHAGE; HEMOSTATICS; HUMANS; INHERITANCE PATTERNS; MALE; MUTATION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 34547889530     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890701513738     Document Type: Review

References (49)

1. Castaman G, Federici AB, Rodeghiero F, Mannnucci PM. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica. 2003;88:94-108.
2. Lee CA, Kessler CM, editors, Proceedings of a Nordic von Willebrand symposium. Haemophilia. 1999;5 suppl 2.
3. Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiations of classic hemophilia (Facor VIII Deficiency) and von Willebrand's disease. J Clin Invest. 1971;50:244-54.
4. Federici AB, Berntorp E, Lee CA. The 80th Anniversary of von Willebrand Disease: History, Management, Research. Haemophilia. 2006;12:563-572.
5. Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol. 2001;14:257-79.
6. Mancuso DJ, Tuley EA, Westfield LA, Lester-Mancuso TI, Le Beau MM, Sorace JM, et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry. 1991;30:253-69.
7. Goodeve A, Eikenboom JCJ, Ginsburg D, Hilbert L, Mazurier C, Peake IR, et al. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor. Thromb Haemost. 2001;85:929-31.
8. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand Factor. Thromb Haemost. 1998;79:456-65.
9. Mazurier C, Rodeghiero F. Recommended abbreviations for von Willebrand factor and its activities. Thromb Haemost. 2001;85:929-31.
10. Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1994;71:520-3.
11. Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease. A report of the Subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103-14.
12. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of VWD in Italy. Haemophilia. 2002;8:607-21.
13. Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia. 2004;10:169-76.
14. Mazurier C, Hilbert L. Type 2 N von Willebrand disease. Current Hematol Rep. 2005;4:350-8.
15. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69:1691-5.
16. Kunicki TJ, Federici AB, Salomon DR, Koziol JA, Head SR, Mondala TS, et al. An association of candidate gene haplotypes and bleeding severity in Von Willebrand Disease (VWD) type 1 pedigrees. Blood. 2004;104:2359-67.
17. Silwer J. von Willebrand's disease in Sweden. Acta Paediat Scand. 1973;238:1-159.
18. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 348 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000;111:1223-9.
19. Rodeghiero F, Castaman G, Tosetto A, Battle J, Baudo F, Cappelletti A, et al. The discriminant power of bleeding history for the diagnosis of von Willebrand disease type 1: an international multicenter study. J Thromb Hemost. 2005;3:2619-26.
20. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Battle J, et al. A quantitative analysis of bleeding symptoms in type 1 of von Willebrand disease: results from a multicenter European Study (MCMDM-1VWD). J Thromb Hemost. 2006;4:774-82.
21. Mannucci PM, Lombardi R, Bader R, Vianello L, Federici AB, Solinas S, et al. Heterogeneity of type I von Willebrand's disease: evidence for a subgroup with an abnormal von Willebrand Factor. Blood. 1985;66:796-802.
22. Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, et al. Evaluation of the PFA-100 System in the diagnosis and therapeutic monitoring of patients with von Willebrand Disease. Thromb Haemost. 1999;82:35-39.
23. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost. 2000;83:127-35.
24. Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease: single center comparison of four different assays. Thromb Haemost. 2000;84:1127-8.
25. Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol. 1995;386:87-92.
26. Meyer D, Fressinaud E, Hilbert L, Ribba AS, Lavergne JM, Mazurier C. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Best Pract Res Clin Haematol. 2001;14:349-64.
27. Schneppenheim R, Federici AB, Budde U, Castaman G, Drewke E, Mannucci PM, et al. Von Willebrand disease type 2 M "Vicenza" in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost. 2000;83:136-40.
28. Castaman G, Missiaglia E, Federici AB, Schneppenheim R, Rodeghiero F. An additional candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2 M Vicenza and the G3864A (R1205H) mutation. Thromb Haemost. 2000;84:350-1.
29. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Battle J, et al. Phenotype and genotyoe of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand disease. Blood. 2007;109:112-121.
30. James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood. 2007;109:145-54.
31. Shelton-Inloes BB, Chebab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletion correlates with the 21 development of alloantibodies in von Willebrand disease. J Clin Invest. 1987;79:1459-65.
32. Mannucci PM, Tamaro G, Narchi G, Candotti G, Federici A, Altieri D, et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand Factor. Eur J Haematol. 1987;39:467-70.
33. Eikenboom JCJ. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol. 2001;14:365-79.
34. Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, et al. Molecular Characterization of a multiethnic Group of 21 Patients with type 3 von Willebrand Disease. Thromb Haemost. 2000;84:536-40.
35. Schneppenheim R, Castaman G, Federici AB, Kreuz W, Marschalek R, Oldenburg J, et al. A commom 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3. J Thromb Haemost. 2007;5:722-8.
36. Mannucci PM. Treatment of von Willebrand disease. N Eng J Med. 2004;351:683-94.
37. Federici AB, Mazurier C, Berntorp E, Lee CA, Sharrer I, Goudemand J, et al. Biological response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103:2032-38.
38. Mannucci PM, Bettega D, Cattaneo M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and haemophilia A. Br J Haematol. 1992;82:87-93.
39. Smith TJ, Gill JC, Ambruso DR. Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol. 1989;31:199-202.
40. Bond L, Bevin D. Myocardial infarction in a patient with hemophilia A treated with DDAVP. N Engl J Med. 1988;318:121.
41. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol. 1988;28:63-5.
42. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coag Fibrin. 2005;16:S17-21.
43. Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Sharrer I, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study on 50 patients. J Thromb Haemost. 2007;5:1115-24.
44. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost. 2002;88:378-9.
45. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med. 1995;125:348-55.
46. Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor VIIa (Novoseven) in the treatment of two patients with type III von Willebrand disease and an inhibitor against von Willebrand factor. Haemostasis. 1996;26:150-4.
47. Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemost. 2003;1:190-2.
48. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coag Fibrin. 2005;16:S23-6.
49. Federici AB, Gianniello F, Canciani MT, Mannucci PM. Secondary long-term prophylaxis in severe patients with von Willebrand disease: an Italian cohort study. Blood. 2005;106:507a, abstract 1782.